Relapsed/Refractory
Criteria to qualify for study: | Drug used in study: |
---|---|
|
LYM 157 A phase 2 front line PET/CT -2 response adapted Brentuximab Vedotin and Nivolumab incorporated and Radiation free management of early stage Classical Hodgkin Lymphoma (Chl) |